$CRWD — AVOID 📊 | 6 MONTHS THESIS

$CRWD — AVOID 📊 | 6 MONTHS THESIS 🎯 FQ1 FY2027 (ends Apr) | reported Jun 03 | Rev $1.4B | EPS $1.10 vs $1.07 🟢 | Margin -2.2% 💡 Consensus expects sustained 30%+ ARR growth and eventual margin expansion to justify the premium. The variant view is that growth will decelerate amid competitive pressure and market saturation, while the current multiple already implies a flawless execution that is unlikely to persist. 📉 Reward/risk: 0.9:1 🏢 Business Quality: 7/10 - Leader in cloud-native endpoint security with high switching costs, strong ARR momentum, and a large TAM, but currently lacks consistent GAAP profitability due to heavy R&D and S&M spend. 📊 Valuation: rich - forward P/E 131x vs peer range 9.0–43.5x, FCF yield ~1.2%, reverse DCF implies negative growth to justify current price; even bull case 43.5x... 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/CRWD0611

🎯 FQ1 FY2027 (ends Apr) | reported Jun 03 | Rev $1.4B | EPS $1.10 vs $1.07 🟢 | Margin -2.2%